Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001224794 | SCV001397016 | likely benign | Hereditary spastic paraplegia 11 | 2024-10-21 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002563059 | SCV003685320 | uncertain significance | Inborn genetic diseases | 2022-09-22 | criteria provided, single submitter | clinical testing | The c.382A>G (p.T128A) alteration is located in exon 2 (coding exon 2) of the SPG11 gene. This alteration results from a A to G substitution at nucleotide position 382, causing the threonine (T) at amino acid position 128 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV005057123 | SCV005725534 | uncertain significance | not specified | 2024-11-27 | criteria provided, single submitter | clinical testing | Variant summary: SPG11 c.382A>G (p.Thr128Ala) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 4e-05 in 251388 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in SPG11 causing Hereditary Spastic Paraplegia, Type 11 (4e-05 vs 0.0011), allowing no conclusion about variant significance. To our knowledge, no occurrence of c.382A>G in individuals affected with Hereditary Spastic Paraplegia, Type 11 and no experimental evidence demonstrating its impact on protein function have been reported. ClinVar contains an entry for this variant (Variation ID: 952649). Based on the evidence outlined above, the variant was classified as uncertain significance. |